Journal on Recent Advances in Pain

Register      Login

VOLUME 6 , ISSUE 1 ( January-April, 2020 ) > List of Articles


COVID-19 and Interventional Pain Practice

Jeshnu P Tople, Gautam Das

Keywords : Chronic Pain, COVID-19, Interventional pain practice, Recommendations

Citation Information : Tople JP, Das G. COVID-19 and Interventional Pain Practice. J Recent Adv Pain 2020; 6 (1):1-3.

DOI: 10.5005/jp-journals-10046-0161

License: CC BY-NC 4.0

Published Online: 25-08-2013

Copyright Statement:  Copyright © 2020; The Author(s).


In December 2019, an outbreak of COVID-19 occurred in Wuhan, China, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The infection became pandemic within next few weeks. The literature regarding interventional pain practice with respect to COVID-19 is scarce. But pathological and structural features of SARS-CoV-2 and SARS-CoV resemble each other and hence long-term sequelae, with respect to chronic pain, similar to severe acute respiratory syndrome (SARS) can be expected with COVID-19. Also, on literature search, we could not find any recommendations or guidelines for interventional pain practice. However, American Society of Regional Anesthesia and Pain Medicine (ASRA) and European Society of Regional Anesthesia and Pain Therapy (ESRA) have jointly put forth the recommendations for neuroaxial and peripheral nerve blocks for current pandemic situation. We are of opinion that with certain modifications these recommendations can be extrapolated for practice of interventional pain management. We propose the recommendations for interventional pain practice for current pandemic situation of COVID-19.

PDF Share
  1. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020;8(4):420–422. DOI: 10.1016/S2213-2600(20)30076-X.
  2. Coronavirus Disease 2019 (COVID-19) [Internet]. Centers for Disease Control and Prevention. 2020 [cited 5 April 2020]. Available from:
  3. Spychalski P, Błażyńska-Spychalska A, Kobiela J. Estimating case fatality rates of COVID-19. Lancet Infect Dis 2020;S1473-3099(20):30234–30236. DOI: 10.1016/S1473-3099(20)30246-2.
  4. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis 2020. ciaa248. DOI: 10.1093/cid/ciaa248.
  5. Ceccarelli M, Berretta M, Rullo EV, et al. Differences and similarities between sever acute respiratory syndrome (SARS)-coronavirus (CoV) and SARS-CoV-2. WWould a rose by another namesmell as sweet? Eur Rev Med Pharmacol Sci 2020;24(5):2781–2783.
  6. Lee N, Hui D, Wu A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348(20):1986–1994. DOI: 10.1056/NEJMoa030685.
  7. Leung TW, Wong KS, Hui AC, et al. Myopathic changes associated with severe acute respiratory syndrome. Arch Neurol 2005;62(7):1113–1117. DOI: 10.1001/archneur.62.7.1113.
  8. Stainsby B, Howitt S, Porr J. Neuromusculoskeletal disorders following SARS: A case series. J Can Chiropr Assoc 2011;55(1):32–39.
  9. Chao CC. Peripheral nerve disease in SARS: Report of a case. Neurology 2003;61(12):1820–1821. DOI: 10.1212/01.WNL.0000099171.26943.D0.
  10. Tsai LK, Hsieh ST, Chao CC, et al. Neuromuscular disorders in severe acute respiratory syndrome. Arch Neurol 2004;61(11):1669–1673. DOI: 10.1001/archneur.61.11.1669.
  11. Moldofsky H, Patcai J. Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; A case-controlled study. BMC Neurology 2011;11(1):37. DOI: 10.1186/1471-2377-11-37.
  12. Herridge MS, Cheung AM, Tansey CM, et al. One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med 2003;348(8):683–693. DOI: 10.1056/NEJMoa022450.
  13. [Internet]. 2020 [cited 8 April 2020]. Available from:
  14. Chen J. Pathogenicity and transmissibility of 2019-nCoV: A quick overview and comparison with other emerging viruses. Microbes Infect 2020;22(2):69–71. DOI: 10.1016/j.micinf.2020.01.004.
  15. [Internet]. 2020 [cited 8 April 2020]. Available from:
  16. van Doremalen N, Bushmaker T, Morris D, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 2020;382(16):1564–1567. DOI: 10.1056/NEJMc2004973.
  17. Kampf G, Todt D, Pfaender S, et al. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect 2020;104(3):246–251. DOI: 10.1016/j.jhin.2020.01.022.
  18. Practice Recommendations on Neuraxial Anesthesia and Peripheral Nerve Blocks during the COVID-19 Pandemic [Internet]. 2020 [cited 5 April 2020]. Available from:
  19. [Internet]. 2020 [cited 5 April 2020]. Available from:
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.